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Distribution of GBM heparan sulfate proteoglycan core protein and
side chains in human glomerular diseases. Using monoclonal antibodies
(mAbs) recognizing either the core protein or the heparan sulfate (HS)
side chain of human GBM heparan sulfate proteoglycan (HSPG), we
investigated their glomerular distribution on cryostat sections of human
kidney tissues. The study involved 95 biopsies comprising twelve
different glomerulopathies. Four normal kidney specimens served as
controls. A homogenous to linear staining of the GBM was observed in
the normal kidney with anti-HSPG-core mAb (JM-72) and anti-HS mAb
(JM-403). In human glomerulopathies the major alteration was a seg-
mental or total absence of GBM staining with anti-HS mAb JM-403,
which is most pronounced in lupus nephritis, membranous glomerulo-
nephritis (GN), minimal change disease and diabetic nephropathy,
whereas the HSPG-core staining by mAb JM-72 was unaltered. In
addition we found HSPG-core protein in the mesangial matrix when this
was increased in membranoproliferative ON Type I, SchOnlein-Henoch
ON, IgA nephropathy, lupus nephritis, diabetic nephropathy and in
focal glomeruloscierosis. Also staining with the anti-HS mAb JM-403
became positive within the mesangium, although to a lesser extent.
Furthermore, amyloid deposits in AL and AA amyloidosis clearly
stained with anti-HSPG-core mAb JM-72, and to a lesser degree with
anti-HS mAb JM-403. Finally, in membranous GN (stage II and III), the
GBM staining with anti-HSPG-core mAb JM-72 became irregular or
granular, probably related to the formation of spikes. In conclusion,
major alterations were observed in the glomerular distribution of HS
and HSPG-core in various human glomerulopathies. The mAbs can be
useful to further delineate the significance of HSPG and HS for
glomerular diseases.
The biochemical and biophysical properties of the glomerular
capillary wall (GCW), which functions both as a size and a
charge selective filter, are, in addition to hemodynamic and
oncotic factors, important determinants of glomerular ultrafil-
tration [1]. The physicochemical basis for the charge-selective
filtration is thought to be an electrostatic repulsion of the
negative charge of albumin and other plasma proteins by the
fixed negative charge of the GCW [2, 3]. Initially it was thought
that sialoglycoproteins, located on the cell membranes of gb-
merular endothelial and epithelial cells, were mainly responsi-
ble for the negative charge of the GCW. Later on it became
clear that also the anionic glycosaminoglycan heparan sulfate
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(HS), which is the side chain of heparan sulfate proteoglycan
(HSPG), present in the glomerular basement membrane (GBM),
was a major determinant of the charge-dependent permeability
of the GCW [4—7]. Enzymatic digestion of HS in the GCW
causes an increased passage of native ferritin and albumin into
the urinary space [4, 5]. Furthermore, intrarenal or intravenous
injection of cationic molecules leads to an increased GBM
permeability due to the neutralization of primarily HS-associ-
ated anionic sites of the GCW [8—121. Recently, we demon-
strated the induction of an acute selective proteinuria after
intravenous injection of a monocbonal antibody (mAb) against
GBM HS [13].
In many types of gbomerular disease, major alterations occur
in the permeability of the GBM, resulting in proteinuria. For
that reason several investigators have tried to relate the status
of GBM HSPG to the onset or existence of proteinuria in many
types of glomerulopathy [14]. Firstly, using cationic probes
both in humans and in experimental animals, a reduction of
GBM anionic sites was found in systemic lupus erythematosus
[15—17], aminonucleoside nephropathy [18], minimal change
disease [19], membranous glomerulonephritis (GN) [20—24],
congenital nephrotic syndrome [25], IgA nephropathy [26, 27]
and diabetic nephropathy [28—30]. Secondly, with biochemical
and immunochemical methods HSPG alterations were observed
in membranous GN [31], polycystic kidney disease [32] and
diabetic nephropathy [33—37]. However, in many of these
studies the methods used (cationic probes, "S-sulfate incorpo-
ration) are not specific for HS and controversies still exist that
hamper a clear interpretation [38—44]. Finally, some reports
have described changes in the immunohistochemical distribu-
tion of HSPG-core protein in several glomerubopathies [45—51].
However, an immunohistochemical analysis of the distribution
of glomerular HS has not been performed so far.
Recently, we developed mAbs against the core protein of
human GBM HSPG [52] and against the HS-side chain of GBM
HSPG [13]. In this paper we describe the gbomerular distribu-
tion of HSPG and HS in twelve different types of human
glomerular diseases using these mAbs in indirect immunofluo-
rescence (IF) on cryostat sections of kidney biopsies. One
major alteration that we observed was a strong decrease or even
absence of GBM staining with anti-HS mAb JM-403 in several
gbomerular diseases, whereas the HSPG-core staining by mAb
JM-72 was unaltered. These results indicate an impaired HS
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Anti-HSPG-core Anti-HS
Characteristic mAb JM-72 mAb JM-403
Isotype IgG 1 1gM
Immunogen human GBM rat glomerular
HSPG HSPG
Species specificity human rat, mouse, human
Binding toa
Human GBM HSPG yes yes
Human GBM HSPG-core yes no
HS-side chain no yes
Staining of the GBMb yes yes
Staining sensitive for no yes
heparitinase°
Binding was studied in ELISA, inhibition ELISA and Western blot
b In indirect immunofluorescence and immunoelectron microscopy
Pretreatment of cryostat kidney sections with heparitinase and
subsequent indirect immunofluorescence
expression or accessibility in several types of human glomerular
diseases.
Methods
Kidney tissue specimens
This study includes 99 renal tissue specimens. Four of them
were control tissues obtained during operation or taken from
cadaveric donor kidneys which were not suitable for transplan-
tation. The remaining 95 renal biopsies originated from the
Departments of Pathology of the University Hospitals of Nij-
megen and Groningen, and were either obtained by percutane-
ous renal biopsy or at autopsy from patients suffering from
various renal diseases. The tissue specimens were snap-frozen
in liquid nitrogen and stored at —70°C. Classification of glomer-
ular disease was established using routine light, immunofluo-
rescence (IF) and if possible electron microscopy.
Antibodies
The two mAbs recognizing different epitopes of human GBM
HSPG used in this study have been described previously [13,
52]. One of them (JM-72) is directed against the core protein;
the other (mAb JM-403) recognizes the HS-side chain of GBM
HSPG. The major characteristics of these mAbs are summa-
rized in Table 1. Immunohistochemical detection of AA amy-
loidosis was done with mAb REU 86.2 against AA amyloid
(Immuno Quality Products, Groningen, The Netherlands).
Inhibition ELISA
Inhibition ELISAs were performed as described previously
[13]. Briefly, a constant amount of mAb (JM-72 or JM-403) was
added to an increasing amount of the following inhibitors: HS
(from bovine kidney; Seikagaku, Tokyo, Japan), human GBM
HSPG and its core protein, isolated as described previously
[53]. These mixtures were tested in ELISAs with GBM HSPG
(for JM-72) or HS (for JM-403) as coated antigens. Results are
expressed as % inhibition of the ELISA signal calculated
as [1 — (A450 + inhibitor/A450 — inhibitor)] x 100%.
Indirect IF
Initially, kidney biopsies were analyzed with JM-72 alone.
Two zm cryostat sections were fixed in acetone for five
minutes. Thereafter, 100 jsl of JM-72 ascites, diluted 1:200 in
PBS containing 1% BSA and 0.05% sodium azide (IF buffer),
were applied to the sections for 30 minutes at room tempera-
ture. Incubations of the sections with non-relevant mAbs with
an IgG1 isotype served as negative controls. After washing with
PBS, binding of JM-72 (anti-GBM HSPG-core) was visualized
with F(ab)2-fragments of FITC-labeled sheep anti-mouse IgG,
heavy and light chains (Cappel-Organon Teknika, Turnhout,
Belgium), 100 d diluted 1:500 in IF buffer. After incubation for
30 minutes in the dark at room temperature, the sections were
washed with PBS and embedded in Aquamount. Later on,
when the anti-HS mAb JM-403 became available, renal biopsies
were double-stained with anti-HS mAb JM-403 and mAb JM-72
(anti-HSPG-core). Sequential incubations were done as fol-
lows: (a) mAb JM-403 (1:200 dilution of ascites fluid in IF
buffer); (b) FITC-labeled goat anti-mouse 1gM, Fc-specific
(Nordic, Tilburg, The Netherlands, 1:100 in IF buffer); (c) mAb
JM-72 (1:200 dilution of ascites fluid in IF buffer containing 5%
normal human serum); (d) TRITC-labeled goat anti-mouse IgG1
(Nordic, 1:25 in IF buffer containing 5% normal human serum
and 10 sg/ml mouse 1gM to prevent any cross reactivity with
mAb JM-403), The double staining experiments included the
following controls: (a) omitting mAb JM-403 or JM-72 or both;
(b) incubating mAb JM-403 or JM-72 with the conjugate used
for the detection of the other mAb in the double staining.
Sections were examined on a Leitz ortholux microscope
equipped with a Ploemopak epi-illuminator.
Results
Characteristics of the anti-HSPG mAbs
The two mAbs used in this study recognize different epitopes
of GBM HSPG (Table 1, Fig. 1). The mAb JM-72 is directed
against an epitope on the core protein of human GBM HSPG
(Fig. 1A), whereas mAb JM-403 recognizes an epitope on the
HS-side chain of HSPG (Fig. 1B). Although mAb JM-403 was
obtained after immunization with rat glomerular HSPG, this
mAb cross reacts with the HS-side chain of human GBM HSPG
in ELISA and indirect IF on human kidney sections. The
glomerular staining patterns of these mAbs in normal human
kidney are shown by a double staining technique in the indirect
IF in Figure 2. A strong linear staining of the GBM is observed
with mAb JM-72 (Fig. 2A). A homogeneous, fine granular
staining was seen along the GBM with anti-HS mAb JM-403
(Fig. 2B). In normal kidney biopsies of young individuals a very
faint staining of the mesangium was observed with both mAbs,
but this staining increased with advanced age if paralleled by an
expansion of the mesangium.
Alterations in HSPG distribution in glomerular diseases
The various types of glomerulopathies and the number of
biopsies that were analyzed for their HSPG distribution are
listed in Table 2. Less biopsies were available for the evaluation
of JM-403 staining (N = 74) compared to mAb JM-72 (N = 95),
since JM-403 was produced and characterized later, and for
some biopsies, tissue was not available. The alterations in
glomerular HSPG immunolocalization can be categorized as
follows: (a) the most important finding was a segmental or total
absence of GBM staining with anti-H S mAb JM-403 in various
glomerulopathies; in addition (b) the presence of HSPG in
Table 1. Characteristics of anti-human GBM HSPG-core mAb JM-72
and anti-HS mAb JM-403
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Fig. 1. Antigen specificity of mAb JM-72 (A) and inAb JM-403 (B), demonstrated in the inhibition ELISA. Human GBM HSPG was used as coated
antigen in (A), HS in (B). A dose-dependent inhibition of mAb JM-72 (A) was found with intact GBM HSPG (—h—) and its core protein (_*_), but
not by HS (—0—). MAb JM-403 (B) was inhibited in a dose-dependent manner by intact GBM HSPG (—Li—) and HS (—0-), but not by the core protein
of GBM HSPG (_*_).
Fig. 2. HSPG localization in the normal human kidney. Indirect IF on normal human kidney cryostat sections with anti-HSPG-core mAb JM-72
(A) and anti-HS mAb JM-403 (B) in a double staining technique. In this control kidney there is also positive staining of the mesangium, due to
age-related expansion of the mesangial matrix. Insert in (B) demonstrates the GBM staining of mAb JM-403 at a higher magnification (A and B x
260, insert x 450).
expanded mesangial matrix in several glomerulopathies; (C)the
presence of HSPG in glomerular amyloid deposits; and (d) an
irregular GBM staining in stage II and III membranous GN with
anti-HSPG-core mAb JM-72.
Decreased anti-HS mAb JM-403 staining. The majority of
biopsies investigated in this study with anti-HS mAb JM-403
showed a segmental or total absence of GBM staining (Table 2).
This phenomenon was most pronounced in SLE nephritis,
membranous GN, minimal change disease and diabetic ne-
phropathy and was not observed in IgA nephropathy or Al-
port's syndrome. In all other glomerulopathies listed in Table 2,
a lesser degree of reduced GBM staining with JM-403 was
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Table 2. Types of glomerulopathies studied with anti-HSPG-core
mAb JM-72 and anti-HS mAb JM-403 together with the GBM
staining pattern of mAb JM-403
Glomerulopathy JM72a.b
JM-4O3
Normal Segmental Absent
Proliferative
Membranoproliferative GNd 6 2 1
type I
Crescentic GN 7 2 4
Diffuse endocapillary GN 2 1
(post-infectious)
SchOnlein-Henoch purpura 4 1 1
IgA nephropathy 4 3
Lupus nephritis 13 1 12
(WHO class III, IV and V)
Non-proliferative
Minimal change disease 7 3 3
Focal glomerulosclerosis 8 1 3 1
Membranous GN 6 1 4
(Stage II and III)
Other
Diabetic nephropathy 13 2 5 3
(nodular and diffuse)
Alport's syndrome 2 1
Amyloidosis
AL 7 1 4
AA 16 3 10 1
a The numbers of biopsies examined with each mAb are given
b For JM-72 the GBM staining was normal in all biopsies studied
C For anti-HS mAb JM-403 biopsies were categorized according to
their GBM staining patternd GN = glomerulonephritis
observed. Although the decrease or absence of anti-HS staining
may be related to the nature and progression of the disease, we
were not able to correlate the GBM staining pattern with
anti-HS mAb JM-403 to the severity of the disease. No differ-
ences were observed between patients with focal (N = 3) or
diffuse (N = 3) crescentic GN, patients with WHO class III (N
= 2), class IV (N = 8) or class V (N = 3) lupus nephritis,
patients with stage II (N = 4) or stage III (N = 1) membranous
GN, and patients with nodular (N = 4) or diffuse (N = 6)
diabetic nephropathy. We also did not observe an association
between the GBM staining for HS and the degree of proteinuria.
The most striking observation in this respect is that in patients
with minimal lesions glomerulopathy who were in remission (N
= 4), the decrease in HS staining was identical to those who
were still nephrotic (N = 2). In spite of the clear decrease in
JM-403 staining, all biopsies showed a normal staining of the
GBM with the anti-HSPG-core mAb JM-72 as can be seen in the
double staining shown in Figure 3 for lupus nephritis, minimal
change disease, and diabetic nephropathy, respectively.
HSPG in expanded mesangial matrix. The HSPG-core pro-
tein could be demonstrated in mesangial areas of kidney spec-
imens showing expansion of mesangial matrix (Table 3). This
presence of HSPG in the mesangium was seen in membrano-
proliferative GN type I (Fig. 4A), SchOnlein-Henoch GN, IgA
nephropathy, lupus nephritis (Fig. 3A), diabetic nephropathy,
mostly in the noduli (Fig. 3E), and in focal glomerulosclerosis
(Fig. 4B). However, an increase in mesangial matrix was not
observed in all biopsies of the aforementioned glomerular
diseases, and in these biopsies HSPG could not be demon-
strated in the mesangium (Table 3). The mesangial HS staining
with mAb JM-403 was less clear than for the HSPG-core (Table
3). The intensity of the mesangial staining paralleled the inten-
sity of the HS-staining in the GBM; if the GBM staining was
decreased or negative, the mesangium showed also a decreased
or negative staining despite the expansion, as illustrated for
lupus nephritis in Fig. 3B and the diabetic nephropathy in Fig.
3F. However, in biopsies showing expansion of mesangial
matrix in combination with an unaffected HS-staining in the
GBM, HS could be demonstrated in the mesangial areas. This
relation between GBM and mesangial HS staining is illustrated
in Figure 4C in a biopsy with focal glomerulosclerosis, although
in the majority of cases with focal glorneruloscierosis (Table 2)
the HS staining of the GBM and the mesangium was reduced.
HSPG in glomerular amyloid. A brilliant staining was ob-
served with anti-HSPG-core mAb JM-72 of the amyloid depos-
its, localized within the mesangial areas and sometimes also
along the capillary wall in AL (Fig. 5A) as well as in AA (Fig.
5B) amyloidosis (Table 4). These forms of amyloidosis were
distinguished on clinical features and/or the use of an anti-AA
amyloid mAb. The GBM staining with anti-HSPG-core mAb
JM-72 was unaltered in these biopsies. In 10 out of 19 biopsies
with amyloidosis, staining of the amyloid deposits was seen
with anti-HS mAb JM-403 (Fig. 5C),although the staining was
sometimes weak. Although the numbers were small, it seemed
that a positive HS staining was more prevalent in AA amyloid-
osis than in AL.
Membranous GN. An irregular, granular staining of the GBM
was observed with anti-HSPG-core mAb JM-72 in all biopsies
with stage II and III membranous GN (Fig. 6). This irregular,
moth-eaten pattern was not seen in every capillary loop and was
in all probability related to the formation of spikes. Since the
anti-HS staining was negative in four out of five cases with
membranous nephropathy (Table 2), this also suggests that the
newly formed basement membrane matrix at the sites of spike
formation is negative for HS.
Normal distribution of HSPG and HS
A normal glomerular staining with anti-HSPG-core mAb
JM-72 (linear GBM and in general no mesangial staining) was
observed in crescentic GN, minimal change disease and Al-
port's syndrome. No alterations in GBM staining with anti-HS
mAb JM-403 were observed in IgA nephropathy and Alport's
syndrome and in some kidney biopsies belonging to other
glomerulopathies (Table 2).
All control experiments (Methods) we performed in the
indirect IF and the double staining experiments were negative.
Discussion
In this study, the glomerular HSPG distribution was analyzed
in human glomerulopathies by indirect IF, using mAbs specific
for the HSPG-core protein and for the strongly anionic HS-side
chains of HSPG, which are thought to be main determinants of
the charge selective filter of the GCW. Although other reports
have described the distribution of the HSPG-core protein in
several glomerular diseases [45—511, the present study used an
unique combination of mAbs, which permitted a comparison of
the HS-staining with that for the HSPG-core protein. Since the
anti-HSPG-core mAb JM-72 had a different isotype compared
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Fig. 3. HSPG localization in some glomerulopathies. Double staining of anti-HSPG-core mAb JM-72 (A, C and E) and anti-HS mAb JM-403 (B,
D and F) in indirect IF on kidney sections of lupus nephritis (A and B), minimal change disease (C and D) and diabetic nephropathy (E and F). Note
the strongly decreased anti-HS staining, accompanied with an unaltered anti-HSPG-core staining. Arrows in A and asterisks in E indicate the
staining of the expanded mesangium with anti-HSPG-core mAb JM-72 (A and B x 360; C and D x 440; E and F x 220).
to anti-HS mAb JM-403 (IgG1 vs. 1gM), biopsies could be
studied using a double staining technique.
The most remarkable finding was a segmental or global
decrease or even absent staining of anti-HS mAb JM-403
accompanied by a normal staining for HSPG-core protein in
various glomerular diseases, most notably in lupus nephritis,
membranous GN, minimal change disease, and diabetic ne-
phropathy, while it was normal in IgA nephropathy and Al-
port's syndrome. This decrease can be due firstly to a decreased
HS expression in the GBM as a consequence of an impaired
synthesis or enhanced degradation of HS. Alterations in GBM
HS have been described for diabetic nephropathy [33—37] and
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Fig. 4. Presence of HSPG in expanded mesangial matrix. Indirect IF with anti-HSPG-core mAb JM-72 (A and B) or anti-HS mAb JM-403 (C)
demonstrates the presence of HSPG in mesangial matrix in membranoproliferative GN Type 1(A), and focal glomerulosclerosis (B and C). B and
C were carried out by a double staining, arrows indicate the increased mesangial matrix (A X 310; B and C >< 260).
Table 3. Staining of the mesangial matrix with anti-HSPG core mAb
JM-72 and anti-HS mAb JM-403
Glomerulopathy
Anti-HSPG-core
mAb JM-72
Anti-HS
mAb JM-403
Membranoproliferative GN
type I 5/6k 2/3
Schönlein-Henoch GN 1/4 0/4
IgA nephropathy 2/4 1/3
Lupus nephritis 9/13 0/13
Focal glomerulosclerosis 4/8 1/5
Diabetic nephropathy 11/13 2/8
Number of positive specimens/specimens studied are given
for an experimental model of membranous GN [31]. However,
in all glomerulopathies showing a segmental or complete ab-
sence of JM-403 staining, anti-HSPG-core staining was normal,
which indicates that the HSPG-core expression was unaltered.
Secondly, the decrease of JM-403 staining might be due to a
blocking effect of cationic molecules or immune complexes,
that become bound to the GBM by charge-charge interactions.
With cationic probes, various investigators found an impaired
anionic charge of the GCW in experimental and human ne-
phropathies [15—30]. In addition, a number of studies [15, 54—63]
showed the involvement of endogenous cationic molecules in
the pathogenesis of glomerular diseases. In one study the GBM
binding of basic proteins was accompanied by a decrease of the
anionic charge of the GBM and onset of proteinuria [60]. It is
tempting to speculate that our results, demonstrating specifi-
cally a decrease or absence of GBM HS staining may be related
to GBM binding of cationic proteins or immune complexes,
leading to a decrease of the net negative charge of the GBM, as
suggested for SLE nephritis [15—17, 54—56], minimal change
disease [58, 64] and membranous GN [20—24]. The relevance of
the JM-403 HS-epitope for the charge-selective properties of
the GBM is suggested by our recent observation that JM-403 is
able to induce an acute selective proteinuria in rats after a single
intravenous injection [13]. Recent work from our laboratory
[65, 66] and that of others [54] points towards a role of histones
in lupus nephritis. Recently, the glomerular localization of
histones was demonstrated in human SLE kidney biopsies [55].
The binding of histones to the GBM might explain our immu-
nohistochemical findings in the SLE kidney biopsies showing a
complete absence of JM-403 staining, accompanied by an
unaltered JM-72 binding. Preliminary data from our laboratory
show that cationic molecules like histones are indeed able to
inhibit the binding of JM-403 to HS in ELISA, but not the
binding of JM-72 to HSPG (unpublished data). Whether a
similar mechanism is also true for other glomerular diseases
remains to be elucidated and is under current investigation.
In the present study, we were not able to correlate the GBM
staining pattern with anti-HS mAb JM-403 to clinical parame-
ters of the patients, especially proteinuria. This may be due to
the retrospective character of this study. However, we have
preliminary data in the adriamycin model in the rat demonstrat-
ing a significant correlation between the GBM staining with
mAb JM-403 and the fractional urinary excretion of albumin in
course of time. It is attractive to hypothesize that an increase in
urinary albumin excretion may be the result of an altered HS
expression/accessibility in the GBM. An alternative explana-
tion for the decreased HS staining of the GBM could be an
altered HS metabolism as a consequence of the high levels of
proteinuria. In that case, a decreased anti-HS staining would be
an aspecific phenomenon related to the presence of proteinuria.
An argument against the latter explanation is the fact that we
found a normal HS staining in IgA nephropathy, Alport's
syndrome and some biopsies from several other glomerular
diseases with increased proteinuria.
A second alteration we observed in glomerular HSPG distri-
bution deals with the presence of HSPG in areas with increased
mesangial matrix production, suggesting the production of
HSPG by mesangial cells in these glomerular diseases (Table 3).
Normally, chondroitin sulfate proteoglycan appears to be con-
centrated in the mesangial matrix [67] and is the major proteo-
glycan produced by mesangial cells in culture [68—70]. How-
ever, in several experimental and human glomerular diseases,
an expansion of the mesangium is accompanied by an altered
composition of the mesangial matrix [71—75], one of them
showing the presence of HSPG [71].
In amyloidosis we observed a brilliant staining of the amyloid
deposits with anti-HSPG-core mAb JM-72 and in some, but not
all cases with anti-HS mAb JM-403. The presence of HSPG in
various forms of amyloid has been known for several years
[reviewed in 76], and was recently demonstrated for neural and
FIg. 5. Presence of HSPG in amyloid deposits. Indirect IF with anti-HSPQ-core mAt, TM-fl (A and B) or anti-HS mAb JM-403 (C) demonstrating
the presence of HSPG in AL (A) and AA (B and C) amyloidosis (A x 190; B x 290; C x 230).
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Fig. 6. Distribution of HSPG-core protein in membranous GN. Indirect IF with anti-HSPG-core mAb JM-72. Overview of a glornerulus (A'..
Magnification of a part of a glomerulus (B), demonstrating the irregular, moth-eaten OHM staining as indicated by arrows (A X 330; B X 1180).
Table 4. Staining of the amyloid deposits with anti-HSPG-core mAb
JM-72 and anti-HS mAb JM-403
Type
Anti-HSPG-core
mAb JM-72
Anti-HS
mAb JM-403
AL amyloidosis 7/7a 1/5
AA amyloidosis 16/16 9/14
a Number of positive specimens/specimens studied are given
renal AA amyloidosis by immunohistochemical methods using
antibodies specific for the HS-side chain and the core protein of
HSPG [77—811. Our study confirms and extends these data,
since we also demonstrated the presence of HSPG in AL
amyloidosis. In amyloidosis, the presence of intrinsic basement
membrane components is not restricted to HSPG, since several
other basement membrane components like collagen type IV,
fibronectin and laminin, have been found in amyloid deposits
[76].
The irregular, moth-eaten GBM staining that we observed in
stage II and III membranous GN with our anti-HSPG-core mAb
JM-72 is in agreement with the findings of others, showing the
presence of HSPG in the spikes, whereas the immune deposits
were negative [46, 50], and suggests that HSPG is a constituent
of the newly formed basement membrane material in this
disease.
Except for membranous GN, we found in all glomerulopa-
thies an unaltered linear GBM staining with the anti-HSPG-core
mAb JM-72. The unaltered HSPG-core expression in the GBM
in various glomerulopathies has been found by others [46, 47],
although some reports described a reduced HSPG-core staining
of the GBM in experimental nephrotic syndrome [451 and in
diabetic nephropathy [51]. These differences may be due to
differences in HSPG source and specificity of the antibodies.
The unique combination of mAbs against the HSPG-core
protein and the HS-side chains can be useful to delineate further
the involvement of HSPG and HS in renal pathology, and
perhaps also in other basement membrane disorders and cell-
matrix interactions in vitro and in vivo.
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